---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-046158"
form_type: "8-K"
ticker: "DERM"
cik: "0001867066"
company_name: "Journey Medical Corp"
filed_at: "2026-04-21T23:59:59+00:00"
generated_at: "2026-05-15T05:10:13.879724+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Journey Medical expands Emrosi payer coverage to ~85% of US commercial lives after third GPO contract

## Summary
- Secured contract with third major GPO, expanding Emrosi commercial access from ~100M to >150M lives as of April 1, 2026.
- Approximately 85% of all US commercial lives now have access to Emrosi for treatment of inflammatory rosacea lesions.
- CEO cites milestone for Emrosi launch; expects less reliance on copay bridging and improved profitability as formulary adoption grows.
- Focus remains on converting access into coverage through health plan formulary adoption throughout 2026 and beyond.

## SEC filing metadata
- accession: 0001104659-26-046158
- form_type: 8-K
- ticker: DERM
- cik: 0001867066
- company_name: Journey Medical Corp
- filed_at: 2026-04-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867066/000110465926046158/0001104659-26-046158-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867066/000110465926046158/tm2612310d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-046158
- JSON: https://secwatch.observer/filing/0001104659-26-046158.json
- Plain text: https://secwatch.observer/filing/0001104659-26-046158.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.